Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.
Standard
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. / Katlama, Christine; Deeks, Steven G; Autran, Brigitte; Martinez-Picado, Javier; van Lunzen, Jan; Rouzioux, Christine; Miller, Michael; Vella, Stefano; Schmitz, Joern E; Ahlers, Jeffrey; Richman, Douglas D; Sekaly, Rafick P.
In: LANCET, Vol. 381, No. 9883, 9883, 2013, p. 2109-2117.Research output: SCORING: Contribution to journal › SCORING: Journal article › Transfer › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.
AU - Katlama, Christine
AU - Deeks, Steven G
AU - Autran, Brigitte
AU - Martinez-Picado, Javier
AU - van Lunzen, Jan
AU - Rouzioux, Christine
AU - Miller, Michael
AU - Vella, Stefano
AU - Schmitz, Joern E
AU - Ahlers, Jeffrey
AU - Richman, Douglas D
AU - Sekaly, Rafick P
N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.
PY - 2013
Y1 - 2013
N2 - Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to regimens that are both expensive and associated with toxic effects. A curative intervention will be needed to fully stop the epidemic. The failure to eradicate HIV infection during long-term antiretroviral therapy shows the intrinsic stability of the viral genome in latently infected CD4T cells and other cells, and possibly a sustained low-level viral replication. Heterogeneity in latently infected cell populations and homoeostatic proliferation of infected cells might affect the dynamics of virus production and persistence. Despite potent antiretroviral therapy, chronic immune activation, inflammation, and immune dysfunction persist, and are likely to have important effects on the size and distribution of the viral reservoir. The inability of the immune system to recognise cells harbouring latent virus and to eliminate cells actively producing virus is the biggest challenge to finding a cure. We look at new approaches to unravelling the complex virus-host interactions that lead to persistent infection and latency, and discuss the rationale for combination of novel treatment strategies with available antiretroviral treatment options to cure HIV.
AB - Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to regimens that are both expensive and associated with toxic effects. A curative intervention will be needed to fully stop the epidemic. The failure to eradicate HIV infection during long-term antiretroviral therapy shows the intrinsic stability of the viral genome in latently infected CD4T cells and other cells, and possibly a sustained low-level viral replication. Heterogeneity in latently infected cell populations and homoeostatic proliferation of infected cells might affect the dynamics of virus production and persistence. Despite potent antiretroviral therapy, chronic immune activation, inflammation, and immune dysfunction persist, and are likely to have important effects on the size and distribution of the viral reservoir. The inability of the immune system to recognise cells harbouring latent virus and to eliminate cells actively producing virus is the biggest challenge to finding a cure. We look at new approaches to unravelling the complex virus-host interactions that lead to persistent infection and latency, and discuss the rationale for combination of novel treatment strategies with available antiretroviral treatment options to cure HIV.
KW - Humans
KW - Anti-HIV Agents/pharmacology
KW - CD4-Positive T-Lymphocytes/drug effects/virology
KW - CD8-Positive T-Lymphocytes/drug effects/virology
KW - Drug Therapy, Combination/methods
KW - HIV Infections/drug therapy/virology
KW - HIV-1/drug effects/physiology
KW - RNA, Viral/drug effects/physiology
KW - Receptors, CCR5/drug effects
KW - Virus Latency/drug effects
KW - Virus Replication/drug effects
KW - Humans
KW - Anti-HIV Agents/pharmacology
KW - CD4-Positive T-Lymphocytes/drug effects/virology
KW - CD8-Positive T-Lymphocytes/drug effects/virology
KW - Drug Therapy, Combination/methods
KW - HIV Infections/drug therapy/virology
KW - HIV-1/drug effects/physiology
KW - RNA, Viral/drug effects/physiology
KW - Receptors, CCR5/drug effects
KW - Virus Latency/drug effects
KW - Virus Replication/drug effects
U2 - 10.1016/S0140-6736(13)60104-X
DO - 10.1016/S0140-6736(13)60104-X
M3 - SCORING: Journal article
C2 - 23541541
VL - 381
SP - 2109
EP - 2117
JO - LANCET
JF - LANCET
SN - 0140-6736
IS - 9883
M1 - 9883
ER -
